Guilford (GLFD) - Steadily Rising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Guilford (GLFD) - Steadily Rising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tdinovo who wrote (122)	10/10/1997 5:12:00 PM
From: NeuroInvestment	of 496

It is highly unlikely that GPI-1046 will be taken into the clinic by Amgen.GPI-1234 is more probable, because this second generation neuroimmunophilin has 50 times the potency of 1046. Additionally, since Vertex believes that it has a potential patent claim on a molecule which appears identical to 1046, Guilford/Amgen can sidestep any possible patent disputes by shifting to the next generation, which has no patent ambiguities. NeuroInvestment

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next